Gerald McLaughlin Net Worth

The estimated Net Worth of Gerald W. Mc Laughlin is at least $1.43 Milhão dollars as of 6 December 2018. Mr. Laughlin owns over 17,097 units of Neos Therapeutics Inc stock worth over $28,175 and over the last 6 years he sold NEOS stock worth over $0. In addition, he makes $1,399,430 as President, Chief Executive Officer, e Director at Neos Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. McLaughlin NEOS stock SEC Form 4 insiders trading

Gerald has made over 2 trades of the Neos Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 17,097 units of NEOS stock worth $36,075 on 6 December 2018.

The largest trade he's ever made was buying 17,097 units of Neos Therapeutics Inc stock on 6 December 2018 worth over $36,075. On average, Gerald trades about 2,722 units every 0 days since 2018. As of 6 December 2018 he still owns at least 24,500 units of Neos Therapeutics Inc stock.

You can see the complete history of Mr. Laughlin stock trades at the bottom of the page.

Gerald McLaughlin biography

Gerald W. McLaughlin serves as President, Chief Executive Officer, Director of the Company. From June 2014 until June 2018, he was President and Chief Executive Officer of AgeneBio, a CNS biopharmaceutical company. Prior to this, Mr. McLaughlin served as the Senior Vice President and Chief Commercial Officer of NuPathe Inc. from September 2007 until its acquisition by Teva Pharmaceuticals Industries Ltd. in March 2014. Previously, Mr. McLaughlin was at Endo Pharmaceuticals from 2001 to 2007 and served in a variety of commercial leadership roles at Merck from 1990 to 2001. He holds a B.A. in Economics from Dickinson College and an M.B.A. from Villanova University.

What is the salary of Gerald McLaughlin?

As the President, Chief Executive Officer, e Director of Neos Therapeutics Inc, the total compensation of Gerald McLaughlin at Neos Therapeutics Inc is $1,399,430. There are no executives at Neos Therapeutics Inc getting paid more.

How old is Gerald McLaughlin?

Gerald McLaughlin is 52, he's been the President, Chief Executive Officer, e Director of Neos Therapeutics Inc since 2018. There are 6 older and 3 younger executives at Neos Therapeutics Inc. The oldest executive at Neos Therapeutics Inc is Alan Heller, 66, who is the Independent Chairman of the Board.

What's Gerald McLaughlin's mailing address?

Gerald's mailing address filed with the SEC is C/O AYTU BIOPHARMA, INC., 373 INVERNESS PARKWAY, SUITE 206, ENGLEWOOD, CO, 80112.

Insiders trading at Neos Therapeutics Inc

Over the last 9 years, insiders at Neos Therapeutics Inc have traded over $796,275 worth of Neos Therapeutics Inc stock and bought 558,630 units worth $7,201,055 . The most active insiders traders include Jack W Schuler, James E Deerfield Mgmt L.P...., eBryant Fong. On average, Neos Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $42,698. The most recent stock trade was executed by Richard I Eisenstadt on 12 December 2018, trading 5,000 units of NEOS stock currently worth $10,800.

What does Neos Therapeutics Inc do?

Complete history of Mr. Laughlin stock trades at Neos Therapeutics Inc e Aytu BioPharma Inc

Neos Therapeutics Inc executives and stock owners

Neos Therapeutics Inc executives and other stock owners filed with the SEC include:

• Gerald McLaughlin,
  President, Chief Executive Officer, Director
• Richard Eisenstadt,
  Chief Financial Officer, Treasurer
• John Limongelli,
  Senior Vice President, General Counsel and Corporate Secretary
• Alan Heller,
  Independent Chairman of the Board
• Linda Szyper,
  Independent Director
• John Schmid,
  Independent Director
• Gregory Robitaille,
  Independent Director
• Bryant Fong,
  Independent Director
• James Robinson,
  Independent Director
• Beth Hecht,
  Independent Director
• Vipin K Garg,
  President, CEO & Director
• Juergen Martens,
  Chief Tech/Operations Officer
• Thomas P Mc Donnell,
  Chief Commercial Officer
• Paul R Edick,
  Director
• Partners 2007, L.P.Presidio...,
  
• Dorothy Engelking,
  VP of Regulatory Affairs
• Mark Tengler,
  Chief Technology Officer
• Ralph Essex Capital Corp Ia...,
  
• Andrew G Delaware Street Ca...,
  
• Jack W Schuler,
  10% owner
• Venture Assoicates Ii Llcbu...,
  
• James E Deerfield Mgmt L.P....,